ANL 31.89 Increased By ▲ 0.84 (2.71%)
ASC 19.60 Increased By ▲ 0.59 (3.1%)
ASL 26.74 Decreased By ▼ -0.61 (-2.23%)
AVN 91.00 Decreased By ▼ -0.39 (-0.43%)
BOP 8.38 No Change ▼ 0.00 (0%)
BYCO 12.89 Decreased By ▼ -0.14 (-1.07%)
DGKC 127.75 Decreased By ▼ -3.00 (-2.29%)
EPCL 48.95 Decreased By ▼ -0.49 (-0.99%)
FCCL 24.05 Decreased By ▼ -0.35 (-1.43%)
FFBL 26.45 Decreased By ▼ -0.50 (-1.86%)
FFL 17.25 Decreased By ▼ -0.24 (-1.37%)
HASCOL 12.23 Increased By ▲ 0.33 (2.77%)
HUBC 81.68 Increased By ▲ 0.68 (0.84%)
HUMNL 8.63 Increased By ▲ 0.14 (1.65%)
JSCL 24.17 Decreased By ▼ -0.13 (-0.53%)
KAPCO 43.53 Decreased By ▼ -0.10 (-0.23%)
KEL 4.48 Decreased By ▼ -0.22 (-4.68%)
LOTCHEM 15.88 Decreased By ▼ -0.32 (-1.98%)
MLCF 48.26 Decreased By ▼ -1.06 (-2.15%)
PAEL 35.85 Decreased By ▼ -0.35 (-0.97%)
PIBTL 11.21 Decreased By ▼ -0.18 (-1.58%)
POWER 10.32 Decreased By ▼ -0.22 (-2.09%)
PPL 91.16 Decreased By ▼ -1.24 (-1.34%)
PRL 25.65 Decreased By ▼ -1.05 (-3.93%)
PTC 12.95 Increased By ▲ 0.05 (0.39%)
SILK 1.59 Decreased By ▼ -0.02 (-1.24%)
SNGP 48.40 Decreased By ▼ -0.95 (-1.93%)
TRG 165.99 Increased By ▲ 0.09 (0.05%)
UNITY 47.99 Decreased By ▼ -0.31 (-0.64%)
WTL 3.84 Decreased By ▼ -0.15 (-3.76%)
BR100 5,299 Decreased By ▼ -33.85 (-0.63%)
BR30 27,755 Decreased By ▼ -182.1 (-0.65%)
KSE100 48,481 Decreased By ▼ -151.66 (-0.31%)
KSE30 19,548 Decreased By ▼ -77.25 (-0.39%)
World

AstraZeneca may have provided incomplete data from latest COVID trial: US Agency

  • The Data Safety Monitoring Board has expressed concern that AstraZeneca may have included outdated information from the trial
  • AstraZeneca says safety of the vaccine has been extensively studied in phase III clinical trials and peer-reviewed data confirms the vaccine has been generally well tolerated
Updated 23 Mar 2021

(Karachi) Amid speculations about patients developing post-jab blood clots by AstraZeneca's COVID-19 vaccine, the US National Institute of Allergy and Infectious Diseases (NIAID) has showed concern that the British drugmaker may have provided an incomplete data of its vaccine's efficacy, local media reported.

"The Data Safety Monitoring Board (DSMB) has expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the US agency said.

The NIAID stated, "We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible."

Meanwhile, AstraZeneca which developed the vaccine in cooperation with Oxford University, has defended the safety of its product. The firm stated that the safety of the vaccine has been extensively studied in phase III clinical trials and peer-reviewed data confirms the vaccine has been generally well tolerated.

Earlier, several European and Scandinavian states including Denmark, Norway and Iceland temporarily suspended the use of AstraZeneca's Covid-19 vaccine after fears of developing post-jab blood clots. Later, they resumed AstraZeneca vaccinations after the European Medicines Agency said hat the jab is "safe and effective" and is not linked to an increased risk of blood clots.

In September 2020, AstraZeneca had suspended global trials of its experimental coronavirus vaccine after an unexplained illness in a participant in Britain.

The vaccine had been described by the World Health Organization as probably the world's leading candidate and the furthest developed.